Report cover image

Global Pneumococcal Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 191 Pages
SKU # APRC20280628

Description

Summary

According to APO Research, the global Pneumococcal Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Pneumococcal Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Pneumococcal Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Pneumococcal Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Pneumococcal Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Pneumococcal Vaccine market include MSD, Sanofipasteur, CDIBP, GSK and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pneumococcal Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Pneumococcal Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pneumococcal Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pneumococcal Vaccine sales, projected growth trends, production technology, application and end-user industry.

Pneumococcal Vaccine Segment by Company

MSD
Sanofipasteur
CDIBP
GSK
Pfizer
Pneumococcal Vaccine Segment by Type

PCV 10
PCV 7/13
PPSV 23
Pneumococcal Vaccine Segment by Application

Child
Adult
Pneumococcal Vaccine Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Colombia
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Pneumococcal Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pneumococcal Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pneumococcal Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Pneumococcal Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Vaccine industry.
Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pneumococcal Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Pneumococcal Vaccine Sales Value (2020-2031)
1.2.2 Global Pneumococcal Vaccine Sales Volume (2020-2031)
1.2.3 Global Pneumococcal Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Pneumococcal Vaccine Market Dynamics
2.1 Pneumococcal Vaccine Industry Trends
2.2 Pneumococcal Vaccine Industry Drivers
2.3 Pneumococcal Vaccine Industry Opportunities and Challenges
2.4 Pneumococcal Vaccine Industry Restraints
3 Pneumococcal Vaccine Market by Company
3.1 Global Pneumococcal Vaccine Company Revenue Ranking in 2024
3.2 Global Pneumococcal Vaccine Revenue by Company (2020-2025)
3.3 Global Pneumococcal Vaccine Sales Volume by Company (2020-2025)
3.4 Global Pneumococcal Vaccine Average Price by Company (2020-2025)
3.5 Global Pneumococcal Vaccine Company Ranking (2023-2025)
3.6 Global Pneumococcal Vaccine Company Manufacturing Base and Headquarters
3.7 Global Pneumococcal Vaccine Company Product Type and Application
3.8 Global Pneumococcal Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Pneumococcal Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Pneumococcal Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Vaccine Market by Type
4.1 Pneumococcal Vaccine Type Introduction
4.1.1 PCV 10
4.1.2 PCV 7/13
4.1.3 PPSV 23
4.2 Global Pneumococcal Vaccine Sales Volume by Type
4.2.1 Global Pneumococcal Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Pneumococcal Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Pneumococcal Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Pneumococcal Vaccine Sales Value by Type
4.3.1 Global Pneumococcal Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Pneumococcal Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Pneumococcal Vaccine Sales Value Share by Type (2020-2031)
5 Pneumococcal Vaccine Market by Application
5.1 Pneumococcal Vaccine Application Introduction
5.1.1 Child
5.1.2 Adult
5.2 Global Pneumococcal Vaccine Sales Volume by Application
5.2.1 Global Pneumococcal Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Pneumococcal Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Pneumococcal Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Pneumococcal Vaccine Sales Value by Application
5.3.1 Global Pneumococcal Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Pneumococcal Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Pneumococcal Vaccine Sales Value Share by Application (2020-2031)
6 Pneumococcal Vaccine Regional Sales and Value Analysis
6.1 Global Pneumococcal Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Pneumococcal Vaccine Sales by Region (2020-2031)
6.2.1 Global Pneumococcal Vaccine Sales by Region: 2020-2025
6.2.2 Global Pneumococcal Vaccine Sales by Region (2026-2031)
6.3 Global Pneumococcal Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Pneumococcal Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Pneumococcal Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Pneumococcal Vaccine Sales Value by Region (2026-2031)
6.5 Global Pneumococcal Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Pneumococcal Vaccine Sales Value (2020-2031)
6.6.2 North America Pneumococcal Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Pneumococcal Vaccine Sales Value (2020-2031)
6.7.2 Europe Pneumococcal Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Pneumococcal Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Pneumococcal Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Pneumococcal Vaccine Sales Value (2020-2031)
6.9.2 South America Pneumococcal Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Pneumococcal Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Pneumococcal Vaccine Sales Value Share by Country, 2024 VS 2031
7 Pneumococcal Vaccine Country-level Sales and Value Analysis
7.1 Global Pneumococcal Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Pneumococcal Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Pneumococcal Vaccine Sales by Country (2020-2031)
7.3.1 Global Pneumococcal Vaccine Sales by Country (2020-2025)
7.3.2 Global Pneumococcal Vaccine Sales by Country (2026-2031)
7.4 Global Pneumococcal Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Pneumococcal Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Pneumococcal Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Pneumococcal Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Pneumococcal Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Pneumococcal Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 MSD
8.1.1 MSD Comapny Information
8.1.2 MSD Business Overview
8.1.3 MSD Pneumococcal Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 MSD Pneumococcal Vaccine Product Portfolio
8.1.5 MSD Recent Developments
8.2 Sanofipasteur
8.2.1 Sanofipasteur Comapny Information
8.2.2 Sanofipasteur Business Overview
8.2.3 Sanofipasteur Pneumococcal Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
8.2.5 Sanofipasteur Recent Developments
8.3 CDIBP
8.3.1 CDIBP Comapny Information
8.3.2 CDIBP Business Overview
8.3.3 CDIBP Pneumococcal Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 CDIBP Pneumococcal Vaccine Product Portfolio
8.3.5 CDIBP Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Pneumococcal Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 GSK Pneumococcal Vaccine Product Portfolio
8.4.5 GSK Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Pneumococcal Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Pfizer Pneumococcal Vaccine Product Portfolio
8.5.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Pneumococcal Vaccine Value Chain Analysis
9.1.1 Pneumococcal Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Pneumococcal Vaccine Sales Mode & Process
9.2 Pneumococcal Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Pneumococcal Vaccine Distributors
9.2.3 Pneumococcal Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.